Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

S-TARget Achieves In Vivo Proof of Concept for Its Allergy Vaccine SG100

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
SG100 is being developed for the prevention and therapy of severe allergic asthma caused by house dust mite (HDM) allergens.

In a study of SG100 in naïve rhesus monkeys, S-TARget has demonstrated that repeated injections of the candidate vaccine induced a Th1 cell mediated memory immune response against natural HDM allergens. A Th1 immune response is considered a “healthy” immune response to allergens. By contrast, a Th2-mediated immune response can lead to allergic diseases—which in the case of exposure to HDM allergens include severe and persistent asthma. The study has also shown that SG100 can be safely applied in a relevant animal model.

“We are excited about the data from this study as it shows that S-TARget’s technology platform is safe and efficacious in a highly relevant animal model”, commented Geert Mudde, PhD, Chief Scientific Officer of S-TARget and Co-founder of the company.

Dr Mudde continued: “Based on this proof-of-concept study, we are currently initiating a follow-on study with SG100 in a clinically highly predictive non human primate animal model of house dust mite induced allergic asthma. The goal is to demonstrate the ability of SG100 to not only induce a Th1-mediated immune response, but to remodel existing ‘allergic’ Th2 cells into ‘healthy’ Th1 cells, thus triggering a normal immune response to future HDM exposure. SG100 is specifically designed for the human immune system (it will not work in rodents) to achieve exactly this remodeling of allergic Th2-cells. Such remodeling will provide a powerful therapeutic approach to directly address the causes of allergic diseases instead of just treating the symptoms”.

Follow-on study to reduce development risk; data expected in July

“The encouraging results achieved with SG100 are a major milestone for S-TARget”, commented Christof Langer, MBA, Chief Executive Officer and Co-founder of S-TARget. “We look forward to conducting the follow-on study of SG100 as it will be highly predictive of its subsequent development in the clinic. We believe that this approach will facilitate the clinical development. Moreover, it will significantly reduce the development risk of this program, making S-TARget an attractive target for future investors.” S-TARget expects the results of this study to be available in July 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!